Form 4: Teva Pharmaceuticals Director Amir Elstein Acquires Shares
Insider Transaction Filing
Teva Pharmaceuticals Director Amir Elstein acquired 7,242 restricted share units on May 28, 2026, as disclosed in a Form 4 filing.
Summary
- Amir Elstein, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units (RSUs) on May 28, 2026.
- These RSUs represent a contingent right to receive one ordinary share or its cash equivalent upon settlement.
- The RSUs vest on May 28, 2027.
- The filing indicates direct beneficial ownership of these securities by Mr. Elstein.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity-based compensation grant to a director rather than a discretionary purchase or sale of shares.
Positives
- Director acquisition of company shares can signal confidence in the company's future prospects.
- The acquisition of 7,242 restricted share units by a director is a clear indication of equity-based compensation and alignment with shareholder interests.
Future Outlook
The vesting of the restricted share units on May 28, 2027, indicates a future potential increase in the director's direct ownership of Teva Pharmaceutical Industries Ltd. ordinary shares.
Industry Context
StockSavvy.ai notes that insider transactions, such as this acquisition of restricted share units by a director, are common in the pharmaceutical industry as a method of executive compensation and to align management interests with those of shareholders.
Stakeholder Impact
- Shareholders: The acquisition of shares by a director can be seen as a positive signal of confidence in the company's future performance, potentially influencing investor sentiment.
- Management: Reinforces the alignment of management's financial interests with those of the company's shareholders through equity ownership.
Next Steps
- Vesting of 7,242 restricted share units on May 28, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Grant date of restricted share units and earliest transaction date. |
| 05/28/2027 | Vesting date for the restricted share units. |
| 06/01/2026 | Date the Form 4 filing was signed. |
Keywords
Teva Pharmaceuticals, Amir Elstein, Form 4, Restricted Share Units, Director, Insider Trading, SEC Filing, TEVA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.